Equity Overview
Price & Market Data
Price: $0.632
Daily Change: -$0.0585 / 9.26%
Range: $0.624 - $0.70
Market Cap: $3,197,715
Volume: 307,969
Performance Metrics
1 Week: -8.12%
1 Month: -8.36%
3 Months: -35.99%
6 Months: -55.55%
1 Year: -85.74%
YTD: -61.21%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.